Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNeo-Vac-R01 with Sintilimab and Chemotherapy in Advanced Pancreatic Cancer
NCT06888648Phase 2Not yet recruiting
- Sponsor
- Zhejiang University
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iNeo-Vac-R01 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Zhejiang University. Primary endpoint: Occurrence and frequency of Adverse Events and Serious Adverse Events up to 2 years. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
iNeo-Vac-R01
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06888648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06888648.